FTC Issues Additional Three Warning Letters to CBD Companies

2m read

CBD companies should understand and appreciate their potential risk exposure, which is largely governed by the Federal Food, Drug and Cosmetic Act (FD&C Act) and Federal Trade Commission Act (FTC Act). In the letters, the FTC asked that the companies review their marketing claims and back those claims with competent and reliable scientific evidence. Increasing government interest in the CBD space: There is growing government interest in regulating the CBD space, as evidenced by the FTC and FDA 2019 warning letters. The companies in question sold various products containing CBD, including oils, tinctures, capsules, creams, and “gummies.”  Each company asserted its CBD product was able to cure or treat serious health concerns. The other two companies likewise made similar claims that their CBD products could treat pain and other conditions (both physical and psychological), such as anxiety, depression, fibromyalgia, heart disease, and autism.

Article PreviewBy Tonya M. EspositoRenee B. Appel & Jonathan Huie September 17, 2019 POSTED IN CBD/HEMP

On September 10, 2019, the Federal Trade Commission (FTC) sent warning letters to three companies that sold cannabidiol (CBD) products marketed with misleading claims that they could treat serious diseases. The FTC aims to “protect consumers from unfair and deceptive practices in the marketplace,” and accordingly has the responsibility of jointly overseeing marketing and advertising...

Read the full article @ Cannabis Law Report